Clinical trial
Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in…
NCT00380211 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00380211 |
|---|---|
| Title | Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults |
| Official title | A Randomized, Double-Blind Trial Evaluating the Safety and Immunogenicity of an Influenza Vaccine With Reduced Preservative (FluLaval™ TR) and a Standard Influenza Vaccine (Fluarix®) in Subjects Between 18-60 and Over 60 Years of Age. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Influenza vaccine (A/H3N2, A/H1N1, and B strains), Fluarix |
| Enrollment | 660 |
| Start date | Sep 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Sep 25, 2006 |
| Last update posted | Oct 7, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: